KR101474031B1 - 항종양성 다이하이드로피란-2-온 화합물 - Google Patents

항종양성 다이하이드로피란-2-온 화합물 Download PDF

Info

Publication number
KR101474031B1
KR101474031B1 KR1020097000830A KR20097000830A KR101474031B1 KR 101474031 B1 KR101474031 B1 KR 101474031B1 KR 1020097000830 A KR1020097000830 A KR 1020097000830A KR 20097000830 A KR20097000830 A KR 20097000830A KR 101474031 B1 KR101474031 B1 KR 101474031B1
Authority
KR
South Korea
Prior art keywords
substituted
unsubstituted
pharmaceutically acceptable
tautomer
stereoisomer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020097000830A
Other languages
English (en)
Korean (ko)
Other versions
KR20090024261A (ko
Inventor
로페즈 엠 지저스 마틴
몰리네로 라우라 코엘로
베니테즈 호세 페르난도 리예스
비센트 알베르토 로드리게즈
가르시아-이바르롤라 마리아 가르란조
페레즈 카르멘 무르시아
솔로소 안드레스 프란세슈
산초 프란시스코 산체즈
마르챈트 마리아 델 카르멘 쿠에바스
로드리게즈 로겔리오 페르난데즈
Original Assignee
파르마 마르 에스.에이.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 파르마 마르 에스.에이. filed Critical 파르마 마르 에스.에이.
Publication of KR20090024261A publication Critical patent/KR20090024261A/ko
Application granted granted Critical
Publication of KR101474031B1 publication Critical patent/KR101474031B1/ko
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/34—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D309/36—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with oxygen atoms directly attached to ring carbon atoms
    • C07D309/38—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with oxygen atoms directly attached to ring carbon atoms one oxygen atom in position 2 or 4, e.g. pyrones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/32—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyrane Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
KR1020097000830A 2006-06-16 2007-06-15 항종양성 다이하이드로피란-2-온 화합물 Expired - Fee Related KR101474031B1 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP06380173.2 2006-06-16
EP06380173 2006-06-16

Publications (2)

Publication Number Publication Date
KR20090024261A KR20090024261A (ko) 2009-03-06
KR101474031B1 true KR101474031B1 (ko) 2014-12-17

Family

ID=38508885

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020097000830A Expired - Fee Related KR101474031B1 (ko) 2006-06-16 2007-06-15 항종양성 다이하이드로피란-2-온 화합물

Country Status (29)

Country Link
US (2) US8324406B2 (https=)
EP (3) EP2404912A3 (https=)
JP (2) JP5117491B2 (https=)
KR (1) KR101474031B1 (https=)
CN (2) CN101679340B (https=)
AR (1) AR061506A1 (https=)
AT (1) ATE522514T1 (https=)
AU (1) AU2007259257B8 (https=)
BR (2) BRPI0722429A2 (https=)
CA (1) CA2654334C (https=)
CY (1) CY1112103T1 (https=)
DK (1) DK2032551T3 (https=)
ES (1) ES2371942T3 (https=)
HR (1) HRP20110845T1 (https=)
IL (1) IL195676A (https=)
MX (1) MX2008015754A (https=)
MY (1) MY145788A (https=)
NO (2) NO341508B1 (https=)
NZ (1) NZ573706A (https=)
PL (1) PL2032551T3 (https=)
PT (1) PT2032551E (https=)
RS (1) RS52034B (https=)
RU (2) RU2444519C2 (https=)
SG (1) SG174830A1 (https=)
SI (1) SI2032551T1 (https=)
TW (2) TWI373469B (https=)
UA (1) UA97369C2 (https=)
WO (1) WO2007144423A1 (https=)
ZA (1) ZA200810315B (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2231633E (pt) * 2007-12-20 2014-01-20 Pharma Mar Sa Compostos antitumorais
ES2411930T3 (es) 2008-02-20 2013-07-09 Actelion Pharmaceuticals Ltd. Compuestos antibióticos azatricíclicos
RU2501799C2 (ru) 2008-02-22 2013-12-20 Актелион Фармасьютикалз Лтд Поизводные оксазолидинона
BRPI0920895A8 (pt) 2008-10-07 2017-12-26 Actelion Pharmaceuticals Ltd Compostos antibióticos de oxazolidinona tricíclica
KR101667066B1 (ko) 2008-10-10 2016-10-17 액테리온 파마슈티칼 리미티드 옥사졸리디닐 항생제
WO2010149688A2 (en) 2009-06-24 2010-12-29 Pharma Mar, S.A. Antitumoral compounds
GB201309807D0 (en) * 2013-05-31 2013-07-17 Pharma Mar Sau Antibody drug conjugates
CN108467378A (zh) * 2017-02-23 2018-08-31 复旦大学 一种二氢吡喃酮类化合物及其制备方法和用途
HRP20231233T1 (hr) 2017-04-27 2024-01-19 Pharma Mar, S.A. Antitumorski spojevi
CN110790737B (zh) * 2019-11-07 2022-07-22 河南中烟工业有限责任公司 一种2,3-二氢-3,5-二羟基-6-乙基-4h-吡喃-4-酮的制备方法
CN118139851A (zh) 2021-10-22 2024-06-04 法马马有限公司 抗肿瘤化合物
CN117510448A (zh) * 2023-11-13 2024-02-06 贵州中医药大学 一种二氢吡喃酮衍生物及其制备方法与应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005117894A1 (en) 2004-06-03 2005-12-15 Kosan Biosciences Incorporated Leptomycin compounds

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA938019B (en) * 1992-11-13 1995-04-28 Upjohn Co Pyran-2-ones and 5,6-dihydropyran-2-ones useful for treating HIV and other retroviruses
DE69433705T2 (de) * 1993-11-19 2005-03-10 Parke, Davis & Company 5,6-Dihydropyronderivate als Proteaseinhibitoren und Antiviralmittel

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005117894A1 (en) 2004-06-03 2005-12-15 Kosan Biosciences Incorporated Leptomycin compounds

Also Published As

Publication number Publication date
JP5117491B2 (ja) 2013-01-16
NZ573706A (en) 2011-09-30
US20120190870A1 (en) 2012-07-26
RU2011133128A (ru) 2013-02-10
ATE522514T1 (de) 2011-09-15
JP2012021023A (ja) 2012-02-02
JP2009539943A (ja) 2009-11-19
UA97369C2 (ru) 2012-02-10
KR20090024261A (ko) 2009-03-06
MY145788A (en) 2012-04-30
NO20090054L (no) 2009-01-06
IL195676A0 (en) 2009-09-01
ZA200810315B (en) 2010-02-24
AU2007259257B2 (en) 2011-12-08
SG174830A1 (en) 2011-10-28
NO20111248L (no) 2008-12-16
WO2007144423A1 (en) 2007-12-21
EP2404912A3 (en) 2012-07-25
DK2032551T3 (da) 2012-01-02
BRPI0713031A2 (pt) 2013-03-12
US20090186938A1 (en) 2009-07-23
BRPI0722429A2 (pt) 2013-11-26
AU2007259257B8 (en) 2012-04-05
RS52034B (sr) 2012-04-30
RU2009101150A (ru) 2010-07-27
US8501968B2 (en) 2013-08-06
CA2654334A1 (en) 2007-12-21
CN102336730A (zh) 2012-02-01
AU2007259257A8 (en) 2012-04-05
CY1112103T1 (el) 2015-11-04
BRPI0713031B1 (pt) 2020-10-06
CN101679340B (zh) 2013-06-05
PL2032551T3 (pl) 2012-01-31
EP2404913A3 (en) 2012-06-06
HRP20110845T1 (hr) 2011-12-31
ES2371942T3 (es) 2012-01-11
EP2032551B9 (en) 2012-02-29
SI2032551T1 (sl) 2012-01-31
TW201213316A (en) 2012-04-01
PT2032551E (pt) 2011-12-06
NO341508B1 (no) 2017-11-27
IL195676A (en) 2012-06-28
AU2007259257A1 (en) 2007-12-21
BRPI0713031B8 (pt) 2021-05-25
TWI373469B (en) 2012-10-01
US20100048690A2 (en) 2010-02-25
HK1130052A1 (en) 2009-12-18
MX2008015754A (es) 2009-01-12
EP2032551B1 (en) 2011-08-31
CA2654334C (en) 2014-06-10
CN101679340A (zh) 2010-03-24
RU2444519C2 (ru) 2012-03-10
AR061506A1 (es) 2008-09-03
EP2404913A2 (en) 2012-01-11
EP2404912A2 (en) 2012-01-11
EP2032551A1 (en) 2009-03-11
US8324406B2 (en) 2012-12-04
TW200811128A (en) 2008-03-01

Similar Documents

Publication Publication Date Title
KR101474031B1 (ko) 항종양성 다이하이드로피란-2-온 화합물
KR101541436B1 (ko) 항암 화합물
AU2011203085A1 (en) Antitumoral dihydropyran-2-one compounds
HK1130052B (en) Antitumoral dihydropyran-2-one compounds

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

A201 Request for examination
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 6

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 7

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 8

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 9

PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20231212

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20231212